SCHEMBL6027092

SCHEMBL6027092

CC(C)(C)[Si](C)(C)OCCBr.Cc1cccc(C(=O)NCCO[Si](C)(C)C(C)(C)C)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.46
HPGD P15428 3/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
ATM Q13315 1/20 0.42
GRM5 P41594 2/20 0.41
HTR1A P08908 2/20 0.41
HTR2A P28223 2/20 0.41
DRD3 P35462 1/20 0.41
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
LMNA P02545 2/20 0.38
CTSA P10619 2/20 0.35
CNR1 P21554 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.35
TP53 P04637 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6027180 0.94 P2RX7 (0.51) P2RX7HPGDALDH1A1MAPTSMN1; SMN2
SCHEMBL6451392 0.73 P2RX7 (0.67) P2RX7HPGDALDH1A1MAPTSMN1; SMN2
SCHEMBL10707099 0.72 P2RX7 (0.65) P2RX7HPGDALDH1A1MAPTSMN1; SMN2
SCHEMBL30695493 0.70 P2RX7 (0.63) P2RX7HPGDALDH1A1MAPTSMN1; SMN2
SCHEMBL22811277 0.70 P2RX7 (0.67) P2RX7HPGDALDH1A1SMN1; SMN2GRM5
SCHEMBL6027182 0.70 NPSR1 (0.41) HPGDALDH1A1L3MBTL1GRM5RAB9A
Hydrochloric Acid SCHEMBL10709499 0.69 P2RX7 (0.66) P2RX7HPGDALDH1A1MAPTSMN1; SMN2
SCHEMBL18245986 0.69 P2RX7 (0.47) P2RX7ALDH1A1MAPTSMN1; SMN2L3MBTL1
SCHEMBL12163955 0.68 P2RX7 (0.69) P2RX7HPGDSMN1; SMN2GRM5RAB9A
SCHEMBL13116574 0.68 HPGD (0.68) HPGDALDH1A1MAPTSMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1696915-A1 BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY Pfizer, Inc. (US) 2006-09-06 EP disclosed
WO-2005060963-A1 BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY PFIZER INC. (US) 2005-07-07 WO disclosed
US-20050148631-A1 Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AGOURON PHARMACEUTICALS, INC. 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148631-A1 Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B11, HSD11B2 P2RX7 4589/4885HPGD 26/4885ALDH1A1 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.